[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355648-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355648-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","inactivation-of-cdk12-enhances-mitochondrial-efficiency-to-suppress-dna-damage","Inactivation of CDK12 Enhances Mitochondrial Efficiency to Suppress DNA Damage","","Inactivation of cyclin-dependent kinase 12 (CDK12) defines a subset of prostate cancers, yet cellular adaptation to reduced CDK12 transcription elongation remains unclear. To study this response, researchers created a CDK12/CDK13-inhibitor–resistant cell line using THZ531. Genome-wide mRNA stabilization profiling showed selective stabilization of oxidative phosphorylation factors. Loss of CDK12 increased ATP production in cell models and patient tumors, while CDK12/13 dual inhibition drove excessive H2AX DNA damage phosphorylation in sensitive cells, linking CDK12 loss to metabolic rewiring that suppresses DNA damage.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/inactivation-of-cdk12-enhances-mitochondrial-efficiency-to-suppress-dna-damage/355648/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/inactivation-of-cdk12-enhances-mitochondrial-efficiency-to-suppress-dna-damage/355648.png","ImageObject",300,407,{"name":42,"@type":43},"Bintang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main question of the study?","Question",{"text":63,"@type":64},"How prostate cancer cells adapt when CDK12 activity declines, given that CDK12 is a major transcription elongation kinase.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the adaptive response investigated experimentally?",{"text":68,"@type":64},"Researchers developed a CDK12/CDK13 inhibitor-resistant cell line using the dual inhibitor THZ531, then performed targeted drug screening and genome-wide mRNA stabilization mapping.",{"name":70,"@type":61,"acceptedAnswer":71},"What metabolic change is linked to CDK12 loss?",{"text":72,"@type":64},"Loss of CDK12 activity enhances ATP production and selectively stabilizes mRNAs promoting oxidative phosphorylation in resistant cells and in patient tumor samples.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355648,1790899268,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Journal of Cellular and Molecular Medicine   \n ORIGINAL ARTICLE  OPEN ACCESS   \nInactivation ofCDK12 Enhances Mitochondrial Efficiency to Suppress DNA Damage  \nAishwarya Gondane1 | Shivani Yalala1 | Jing Liang1 | Sonja Saira1 | Harri M. Itkonen1,2,3   \n1Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Helsinki, Finland | 2Department of Clinical Molecular Biology, EpiGen, Institute of Clinical Medicine, University of Oslo, Oslo, Norway | 3EpiGen, Medical Division, Akershus University Hospital, Lørenskog, Norway  \nCorrespondence: Harri M. Itkonen ([harri.itkonen@helsinki.fi](harri.itkonen@helsinki.fi))  \nReceived: 14 September 2025 | Revised: 5 March 2026 | Accepted: 11 March 2026  \nKeywords: acquired resistance | cyclin-dependent kinase 12 | genomic instability | metabolism | prostate cancer | SLAM-seq | transcription elongation  \nABSTRACT  \nInactivation of cyclin-dependent kinase 12 (CDK12) characterizes a subset of prostate cancers but it is not understood how cells adapt to declining activity of this major transcription elongation kinase. To probe this response, we developed a cell line resistant to an inhibitor targeting CDK12 and its paralog, CDK13 . CDK13 can compensate for the loss of CDK12, which is why we used the dual inhibitor THZ531 . Targeted drug screening of the parental and resistant cell lines revealed cross-resistance to other transcriptional kinases but no clear acquired point of vulnerability. Using genome-wide mapping of mRNA-stabilization based on metabolic labelling of RNA, we report selective mRNA stabilization of factors promoting oxidative phosphorylation in the resistant cells. We go on to show that loss of CDK12 activity enhances ATP production both in cell line models and in patient tumours. Finally, we show that dual inhibition of CDK12/13 results in excessive phosphorylation of the DNA damage H2AX in prostate cancer cells but not in our CDK12/13 inhibitor-resistant model system. In brief, we propose that inactivation of CDK12 rewires cellular energy metabolism to suppress DNA damage.  \n1 | Background  \nProstate cancer is the most common cancer in males [1] . The disease is driven by the nuclear hormone transcription factor, androgen receptor, which is also the primary target to successfully control prostate cancer [2] . Disappointingly, resistance to anti-androgens occurs frequently, and patients are left with no targeted therapies to control their disease. Better understanding of the anti-androgen-resistant disease holds promise to control prostate cancer.  \nCancer cells exhibit high levels of transcription, and it is therefore unexpected that one of the transcriptional kinases, cyclindependent kinase 12 (CDK12), is inactivated in prostate cancer. CDK12 sustains phosphorylation of RNA polymerase II (RNAPol II) to promote transcription elongation of the particularly long genes [3, 4] and its loss confers resistance to anti-androgens  \n[5] . The other two major transcriptional kinases are CDK7 and CDK9, which regulate transcription initiation and release of the polymerase from promoter-proximal pausing, respectively [6] . Many of the long genes affected due to CDK12 inhibition encode for factors involved in DNA repair, which has been proposed as causal in benefiting cancer cells that have lost this kinase [4] . However, when CDK12 is inactivated in a stable manner, as it is in the clinical setting or when the gene is removed using CRISPR in vitro, transcription of most of the long genes is restored [7] . Understanding how the decrease in CDK12 activity benefits prostate cancer cells therefore remains obscure.  \nThe characterizing feature of the CDK12 mutant tumours is genomic instability, and loss of CDK12 activity is associated with poor prognosis. CDK12 inactivation is most common in prostate cancer but it is also frequently detected in ovarian cancer [8] . Decrease in CDK12 activity can positively regulate transcription  \nThis is an open access a","cbCairSqd6EW8KpD","https://ap.wps.com/l/cbCairSqd6EW8KpD","pdf",2316597,11,"English","# Abstract\n# Background\n## Androgen receptor dependence and resistance\n## Roles of CDK12 and other transcriptional kinases\n## Genomic instability and clinical associations\n# Study design and key findings","[{\"question\":\"What is the main question of the study?\",\"answer\":\"How prostate cancer cells adapt when CDK12 activity declines, given that CDK12 is a major transcription elongation kinase.\"},{\"question\":\"How was the adaptive response investigated experimentally?\",\"answer\":\"Researchers developed a CDK12/CDK13 inhibitor-resistant cell line using the dual inhibitor THZ531, then performed targeted drug screening and genome-wide mRNA stabilization mapping.\"},{\"question\":\"What metabolic change is linked to CDK12 loss?\",\"answer\":\"Loss of CDK12 activity enhances ATP production and selectively stabilizes mRNAs promoting oxidative phosphorylation in resistant cells and in patient tumor samples.\"}]","Inactivation of CDK12 Enhances Mitochondrial Efficiency to Suppress DNA Damage | PDF",1790120292,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/72fe40781b6c78f82faf91ba7be7f8b4.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5404e76a64197df403d1e131baa3a7f.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/020ce7c296d68b3e3f81c377fed20e8a.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7104eb1ee5b45b8c744e1cdb1fdb223c.webp",980,1287]